Tenaya Therapeutics, Inc. $TNYA

What the company doesAI summary of filing

Tenaya Therapeutics is a clinical-stage biotechnology company developing gene therapies and small molecule drugs to treat heart disease. The company's lead programs include TN-201, an AAV9-based gene therapy for MYBPC3-associated hypertrophic cardiomyopathy affecting approximately 120,000 patients in the U.S., and TN-401, an AAV9-based gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy affecting more than 70,000 patients in the U.S., both currently in Phase 1b/2 clinical trials. A third clinical-stage candidate, TN-301, is a small molecule HDAC6 inhibitor being explored for heart failure with preserved ejection fraction and other conditions, having completed Phase 1 testing. The company is pre-revenue and generates no product sales; it has entered a research collaboration with Alnylam Pharmaceuticals that provides reimbursement for research efforts and potential milestone payments. [10-K 2026-03-11]

Segments: TN-201 (gene therapy for MYBPC3-associated HCM), TN-401 (gene therapy for PKP2-associated ARVC), TN-301 (small molecule HDAC6 inhibitor)